TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01361932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video of ED discharge instructions for patient's ED discharge diagnosis
Description: Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
Study: NCT04299763

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Beta-glucan as a Supplement in Type 2 Diabetics
Description: 44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oat Beta-glucan as a Supplement in Type 2 Diabetics
Description: 44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
Study: NCT03721809

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient.
Study: NCT01099657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis for chronic pain
Description: At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction for Chronic Pain
Description: At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
Study: NCT00450736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01840358

Intervention type: OTHER
Group type: OTHER
Intervention: Observation of hypoglycemias frequency 3 days before and after pump initiation
Study: NCT02395055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab (BCD-057)
Description: Adalimumab is a monoclonal antibody against tumor necrosis factor alpha

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (Humira)
Description: Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
Study: NCT02940158

Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- corn

Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- macaroni

Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- white potato

Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- white rice
Study: NCT01711593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage
Description: On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: 200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
Study: NCT02667782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
Study: NCT03580317

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham EA+Carbamazepine
Description: Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham EA+Placebo
Description: The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
Study: NCT02667782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
Study: NCT02787590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo (for Simvastatin)
Study: NCT01219933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: background therapy: 8 mg/kg iv every 4 weeks
Study: NCT03928288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 MG
Description: Medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Placebo capsule
Study: NCT04524650

Intervention type: DIAGNOSTIC_TEST
Intervention: the level of vWF
Description: the peripheral level of vWF

Intervention type: DIAGNOSTIC_TEST
Intervention: the level of vWF
Description: the peripheral level of vWF

Intervention type: DIAGNOSTIC_TEST
Intervention: the level of vWF
Description: the peripheral level of vWF

Intervention type: DIAGNOSTIC_TEST
Intervention: the level of vWF
Description: the peripheral level of vWF
Study: NCT05919641

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
Study: NCT04218071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib at protocol-specified doses for given platelet count

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-
Study: NCT05546255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
Study: NCT02177409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03458858

Intervention type: OTHER
Group type: OTHER
Intervention: Mixed Berry Diet
Description: Mixed Berry Treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate Control Jello
Description: Carbohydrate Control

Intervention type: OTHER
Group type: OTHER
Intervention: Fiber Enriched Jello
Description: Fiber Control

Intervention type: OTHER
Group type: OTHER
Intervention: Low Fiber Mixed Berry Juice
Description: Anthocyanin Control
Study: NCT03657147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video and Question Prompt List
Description: A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
Study: NCT02712424

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DAR-901

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline placebo
Study: NCT01586104

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo cardiac-sparing whole lung IMRT
Study: NCT04202198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pinhole surgical technique only
Description: local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
Study: NCT00003847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biricodar dicitrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT02754583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water, sanitation, and hygiene (WASH) intervention
Description: WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
Study: NCT03492216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for negative EtG test
Description: Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for negative EtG test
Description: Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for positive IsoScreen test
Description: Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for positive IsoScreen test
Description: Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
Study: NCT00299013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLAL-PRED®
Description: COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
Study: NCT01611857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
Study: NCT02940158

Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- small red lentil

Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- small green lentil

Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- corn

Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- macaroni

Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- white potato

Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- white rice
Study: NCT00103207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT02759939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video + Prompt Card
Description: 1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video + Prompt Card
Description: 1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aids + Training
Description: 1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aids + Training
Description: 1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit.
Study: NCT02968277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeWalker Upright
Description: LifeWalker (LW) upright walker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeWalker Upright
Description: LifeWalker (LW) upright walker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeWalker Upright
Description: LifeWalker (LW) upright walker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predicate Device
Description: Individual's personal walker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predicate Device
Description: Individual's personal walker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predicate Device
Description: Individual's personal walker
Study: NCT02513212

Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium Oxalate
Description: Professionally applied liquid

Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium Oxalate
Description: Professionally applied liquid

Intervention type: DRUG
Group type: OTHER
Intervention: Stannous fluoride paste
Description: SnF2 Paste

Intervention type: DRUG
Group type: OTHER
Intervention: Stannous fluoride paste
Description: SnF2 Paste

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush
Description: Marketed manual toothbrush

Intervention type: DEVICE
Group type: OTHER
Intervention: Power toothbrush
Description: Marketed power toothbrush
Study: NCT02237391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIPAP Program
Description: The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: Control group
Study: NCT00738348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sivelstat
Description: sivelstat sodiumhydrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glucose
Description: glucose
Study: NCT00388726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: 1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
Study: NCT02754583

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care WASH intervention
Description: Stand of care WASH arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 20mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: 20mg/kg
Study: NCT01724450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo similar to the carvedilol up titration but wit no active drug.
Study: NCT05449860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes
Description: Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
Study: NCT01261923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alitretinoin
Description: 30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
Study: NCT02754583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 20mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 20mg/kg
Study: NCT02968277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Rollator
Description: A control rollator device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Rollator
Description: A control rollator device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Rollator
Description: A control rollator device